Tarsus Pharmaceuticals is at the forefront of developing innovative therapies aimed at addressing unmet medical needs, particularly in the field of dermatology and ophthalmology. Their flagship product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, is the first FDA-approved treatment specifically for Demodex blepharitis, a condition affecting many patients. This product highlights Tarsus's commitment to creating novel therapies that target specific diseases with limited treatment options. Additionally, the company is advancing its pipeline with investigational therapies like TP-04, a topical gel formulation of lotilaner designed for the potential treatment of papulopustular rosacea, which affects millions of individuals in the U.S. 

The scientific approach of Tarsus Pharmaceuticals is characterized by a focus on developing new categories of treatments that address complex health issues. Their pipeline includes therapies that not only aim to alleviate symptoms but also target underlying causes, such as the eradication of Demodex mites in rosacea patients. Tarsus employs a robust research and development strategy, which is evident in their ongoing clinical trials, including a Phase 2a trial for TP-04. The company’s commitment to patient-centered care and its core values of teamwork and empowerment further distinguish Tarsus in the pharmaceutical landscape, as they strive to make a meaningful impact on the lives of patients suffering from these conditions.

United States

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.

Eye Diseases

Infectious Diseases

Skin Diseases

Tarsus Pharmaceuticals

Demodex Blepharitis

Eye disease

TP-03 is a novel, topical ophthalmic drug that specifically targets the mite's nervous system to kill the mites, thereby treating the underlying cause of disease. The agent has shown consistent results across four Phase 2 studies and almost 100 treated patients to date. Patients report that the drop is comfortable, and no patients in the study discontinued use due to tolerability. TP-03 is currently being developed in a multi-dose, preserved formulation and is expected to begin Phase 3 trials this year.

XDEMVY (TP-03)

Lyme disease

TP-05 is an oral systemic formulation of lotilaner, a well-characterized anti-parasitic agent that paralyzes and kills parasites by selectively inhibiting parasite-specific GABA-Cl channels. Tarsus is studying TP-05 for the prevention of Lyme disease and has initiated a Phase 1 single ascending dose and multiple ascending dose (SAD/MAD) trial to evaluate the safety, tolerability and pharmacokinetics (PK) of TP-05 in healthy volunteers. In addition to Lyme disease, Tarsus is also exploring TP-05 for potential community malaria reduction.

TP-05

Meibomian Gland Disease

TP-03  

Papulopustular rosacea

TP-04 A topical gel formulation of lotilaner, a well-characterized antiparasitic agent that paralyzes and kills Demodex mites by selectively inhibiting parasite-specific 
gamma-aminobutyric acid–chloride channels.
 
Designed to potentially treat PPR and eradicate Demodex mites, which have been reported as highly prevalent in the skin of patients with rosacea, including those with PPR, and may play a key role in triggering inflammatory responses associated with the disease

Tarsus Pharmaceuticals

Company Details